Macsart Beta 50 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 50 mg, formulated for extended release to provide sustained blood pressure control. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and improved cardiovascular outcomes. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to effective management of hypertension and reducing the risk of cardiovascular events such as myocardial infarction and stroke. The combination of these agents offers complementary mechanisms of action, enhancing antihypertensive efficacy while minimizing adverse effects associated with higher doses of individual drugs. Macsart Beta 50 Tablet ER is indicated for the treatment of essential hypertension, particularly in patients requiring multiple antihypertensive agents for optimal blood pressure control. It may also be beneficial in patients with concomitant ischemic heart disease or heart failure where beta-blockade is indicated. Dosage should be individualized based on patient response and tolerability, and therapy should be initiated under medical supervision with regular monitoring of blood pressure, heart rate, and renal function.